N/A
Completed N=84
Stereotactic Body Radiotherapy for Prostate Cancer
Prostate Cancer
Source: ClinicalTrials.gov NCT01352598 ↗
Enrolled (actual)
84
Serious AEs
1.4%
Results posted
Sep 2020
Primary outcomePrimary: Biochemical Control Rate — 71; 0 Participants
Summary
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of organ confined prostate cancer.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Biochemical Control Rate |
71; 0 | — |
| SECONDARY Late Toxicity Rate |
68; 6 | — |
Eligibility Criteria
Inclusion Criteria
- Patient age >= 18 years
- Zubrod performance status of 0-3
- T1-3 N0 M0 adenocarcinoma of the prostate
- Prostate volume ≤ 100 cc
- Signed study-specific consent form
Exclusion Criteria
- Extension of local tumor to involve adjacent organs other than seminal vesicles (T4)
- Prostate volume > 100 cc
- Nodal involvement
- Metastatic disease
- Prior pelvic radiotherapy except as part of combination therapy for prostate cancer
- History of scleroderma
- Patients with psychiatric or addictive disorder that would preclude obtaining informed consent
Data sourced from ClinicalTrials.gov (NCT01352598). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.